PancOne™ Network

Pancreatic cancer has been drastically outpaced by advancements in other cancers and as a result there has been little progress in the fight against pancreatic cancer in the last 40 years. The hard truth of this devastating disease is that 92% of people diagnosed will not live longer than five years. Our researchers believe this is because there are many different subtypes of pancreatic cancer, yet all are traditionally treated with the same type of chemotherapy. They believe that personalized medicines for each subtype may result in higher survival rates.

We know that to accomplish the scale of progress necessary to make a tangible difference in the lives of those with this diagnosis, we need to work collaboratively with global leaders to share knowledge and ideas. That is why we created the Pancreatic Canadian Oncology Network (PancOne)™: a first-of-its-kind network of Canadian investigators at Centres of Excellence from coast to coast who are working together to share ideas, data and findings related to pancreatic cancer. This pan-Canadian initiative aims to better understand this disease to accelerate diagnosis, explore new treatment options for patients and ultimately save more lives.

Since its inception in 2016, PancOne™ has been leveraging information on subtypes from a comprehensive regional population to provide data and insights to national and global institutes and partners to further research into treatment options that will improve patient outcomes. The goal of PancOne™ is to identify these subtypes to find the right treatment for the right patients at the right time, while working to discover new and innovative therapies that provide better patient care for survival and quality of life. Through the funding support of donors to Pancreatic Cancer Canada, PancOne™ will make a significant impact in learning about this disease and treating it in ways never before achieved.

PancOne™ Where You Live

We are continuing to expand our network of medical experts, practitioners and researchers who are innovating research into pancreatic cancer across Canada. Currently, PancOne™ operates at seven medical sites in Canada.
Centres of Excellence:

• Princess Margaret Cancer Centre
• BC Cancer Foundation
• McGill University Health Centre Foundation
• University of Calgary
• QEII Health Sciences Centre Foundation

Supporting Centres:
• Kingston Health Sciences Centre
• The Ottawa Hospital


PancOne™ Genomic Sequencing

The first PancOne™ investments are PanGen (run through the BC Cancer Agency) and COMPASS (run through the University Health Network), which are open to patients with advanced pancreatic cancer, and involve genomic sequencing of tumours followed by ongoing close monitoring for response and resistance to treatment.

The genomic analysis completed by PanGen and COMPASS also enables some patients to be become eligible for clinical trials that could potentially lead to positive outcomes for their subtype of pancreatic cancer. Both PanGen and COMPASS provide data to the EPPIC trial (Enhanced Pancreatic Cancer Profiling for Individualized Care), a collaborative research initiative now largely funded by the Terry Fox Foundation, which aims to uncover if metastatic and primary tumours differ in their genetic makeup. This genomic and clinical data bank is shared by Canadian and international researchers and is the first of its kind in Canada.

PancOne™ began with a project to identify, collect and gather the tumour profiles of 400 patients across Canada. Within the next five years, we hope to have developed a complete understanding of the various subtypes of pancreatic cancer, which will lead to more successful treatment faster, and provide the basis for future research and analysis. With this foundational research well underway, our next step is to discover how best to treat it.

PancOne™ Genomic Sequencing

Current PancOne™ Research

What’s on the horizon?

Strategic, coordinated commitment to research is the single most important investment we can make in the fight against pancreatic cancer. By working in a concerted effort, PancOne™ will help us gain a better understanding of the disease and create a direct impact on every aspect of care. Pancreatic Cancer Canada is currently confirming new investments for the PancOne™ network that will offer a well-rounded portfolio of collaborative research focused on four main priorities:

1. Increasing genomic sequencing
2. Discovering new hereditary subtypes
3. Investigating causation and investing in clinical trials
4. Exploring more personalized medicine and treatment options

We look forward to sharing these new research projects with you soon.

316-4211 Yonge Street
Toronto, ON M2P 2A9
Toll Free: 1-888-726-2269
Charitable Registration Number 84870 1967 RR0001